73734-07-3

Basic information

• Product Name: ethyl 4-(1H-benzimidazol-2-ylamino)piperidine-1-carboxylate
• Synonyms: ethyl 4-(1H-benzimidazol-2-ylamino)piperidine-1-carboxylate;1-Piperidinecarboxylic acid, 4-(1H-benzimidazol-2-ylamino), ethyl ester;4-[(1H-Benzimidazol-2-yl)amino]-1-piperidinecarboxylic acid ethyl ester
• CAS NO: 73734-07-3
• Molecular Formula: C₁₅H₂₀N₄O₂
• Molecular Weight: 288.3449
• EINECS: 277-580-9
• Product Categories: pharmacetical
• Mol File: 73734-07-3.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 482.1°C at 760 mmHg
• Flash Point: 245.4°C
• Appearance: /
• Density: 1.297g/cm³
• Vapor Pressure: 1.88E-09mmHg at 25°C
• Refractive Index: 1.657
• PKA: 11.42±0.10(Predicted)
• CAS DataBase Reference: ethyl 4-(1H-benzimidazol-2-ylamino)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(1H-benzimidazol-2-ylamino)piperidine-1-carboxylate(73734-07-3)
• EPA Substance Registry System: ethyl 4-(1H-benzimidazol-2-ylamino)piperidine-1-carboxylate(73734-07-3)

Safety Data

• Hazardous Substances Data: 73734-07-3(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Medicinal Chemistry, 28, p. 1925, 1985 DOI: 10.1021/jm00150a028

InChI:InChI=1/C15H20N4O2/c1-2-21-15(20)19-9-7-11(8-10-19)16-14-17-12-5-3-4-6-13(12)18-14/h3-6,11H,2,7-10H2,1H3,(H2,16,17,18)

Upstream product

• 4857-06-1 2-chloro-1H-benzoimidazole 
• 58859-46-4 ethyl 4-aminopiperidine-1-carboxylate 
• 73733-70-7 ethyl 4-isothiocyanato-1-piperidinecarboxylate 
• 497-19-8 sodium carbonate 
• 73733-81-0 ethyl 4-{[(2-aminophenyl)aminothioxomethyl]amino}-1-piperidinecarboxylate 
• 74-88-4 methyl iodide 
• 208398-29-2 2-chloro-1-(tetrahydropyran-2-yl)-1H-benzimidazole 

Downstream Products

• 84501-68-8 ethyl 4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate 
• 104472-62-0 (1H-benzimidazol-2-yl)(piperidin-4-yl)amine 
• 247035-03-6 4-{4-(1H-benzimidazol-2-ylamino)piperidin-1-yl}benzoic acid 
• 247035-02-5 ethyl 4-{4-(1H-benzimidazol-2-ylamino)piperidin-1-yl}benzoate 
• 247033-91-6 tert-butyl (2S)-amino-3-[4-[4-{(1-tert-butoxycarbonyl-1H-benzimidazol-2-yl)amino}piperidin-1-yl]benzoylamino]propionate 
• 247033-71-2 tert-butyl (2S)-benzenesulfonylamino-3-[4-{4-(1H-benzimidazol-2-ylamino)piperidin-1-yl}benzoylamino]propionate 
• 247033-88-1 3-{4-[4-(1H-benzoimidazol-2-ylamino)-piperidin-1-yl]-benzoylamino}-2-benzyloxycarbonylamino-propionic acid tert-butyl ester 
• 247034-00-0 3-{4-[4-(1H-benzoimidazol-2-ylamino)-piperidin-1-yl]-benzoylamino}-2-(4-nitro-benzenesulfonylamino)-propionic acid 
• 247033-92-7 tert-butyl (2S)-(butane-1-sulfonyl)amino-3-[4-[4-{(1-tert-butoxycarbonyl-1H-benzimidazol-2-yl)amino}piperidin-1-yl]benzoylamino]propionate 
• 247033-90-5 tert-butyl (2S)-benzyloxycarbonylamino-3-[4-[4-{(1-tert-butoxycarbonyl-1H-benzimidazol-2-yl)amino}piperidin-1-yl]benzoylamino]propionate 
• 247033-97-2 2-(1-{4-[2-tert-butoxycarbonyl-2-(4-fluoro-benzenesulfonylamino)-ethylcarbamoyl]-phenyl}-piperidin-4-ylamino)-benzoimidazole-1-carboxylic acid tert-butyl ester 
• 247033-99-4 2-(1-{4-[2-tert-butoxycarbonyl-2-(4-nitro-benzenesulfonylamino)-ethylcarbamoyl]-phenyl}-piperidin-4-ylamino)-benzoimidazole-1-carboxylic acid tert-butyl ester 
• 247033-95-0 2-(1-{4-[2-tert-butoxycarbonyl-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-phenyl}-piperidin-4-ylamino)-benzoimidazole-1-carboxylic acid tert-butyl ester 
• 73736-50-2 O-desmethyl astemizole 

Relevant articles and documents

METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER

In an aspect, the disclosure pertains to inhibitors of ANGPTL4; synthesis methods for making disclosed compounds; pharmaceutical compositions comprising disclosed compounds; methods of treating disorders of uncontrolled cellular proliferation, e.g., a cancer; and methods of treating a disease associated with an ANGPTL4 dysfunction using disclosed compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Structure-Activity Relationship Studies Reveal New Astemizole Analogues Active against Plasmodium falciparum in Vitro

In the context of drug repositioning and expanding the existing structure-activity relationship around astemizole (AST), a new series of analogues were designed, synthesized, and evaluated for their antiplasmodium activity. Among 46 analogues tested, compounds 21, 30, and 33 displayed high activities against asexual blood stage parasites (PfNF54 IC50 = 0.025-0.043 μM), whereas amide compound 46 additionally showed activity against late-stage gametocytes (stage IV/V; PfLG IC50 = 0.6 ± 0.1 μM) and 860-fold higher selectivity over hERG (46, SI = 43) compared to AST. Several analogues displaying high solubility (Sol > 100 μM) and low cytoxicity in the Chinese hamster ovary (SI > 148) cell line have also been identified.

Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH 1R, but low affinity to hH4R

In literature, a synergism between histamine H1 and H 4 receptor is discussed. Furthermore, it was shown, that the combined application of mepyramine, a H1 antagonist and JNJ7777120, a H 4 receptor ligand leads to a synergistic effect in the acute murine asthma model. Thus, the aim of this study was to develop new hybrid ligands, containing one H1 and one H4 pharmacophor, connected by an appropriate spacer, in order to address both, H1R and H 4R. Within this study, we synthesized nine hybrid compounds, which were pharmacologically characterized at hH1R and hH4R. The new compounds revealed (high) affinity to hH1R, but showed only low affinity to hH4R. Additionally, we performed molecular dynamic studies for some selected compounds at hH1R, in order to obtain information about the binding mode of these compounds on molecular level.